ASLAN Pharmaceuticals announced that the results from the dose escalation portion of the completed Phase 1b Proof-of-Concept study of ASLAN004 in atopic dermatitis (AD) have been accepted for poster presentation at the 2022 Winter Clinical Dermatology Conference, to be held in Koloa, Hawaii, January 14-19, 2022. The poster will provide further details on the safety, tolerability and efficacy of ASLAN004 in the dose escalation portion of the multiple ascending dose study in 25 patients. The Company also announced these data will be presented in an encore presentation at the MauiDerm Conference, held in Maui, Hawaii, January 24-28.

ASLAN004 is a potential first-in-class monoclonal antibody targeting the IL-13 receptor, with the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen for patients. In September 2021, ASLAN announced positive results from the Phase 1b Proof-of-Concept study and supported its potential as a differentiated, novel treatment for AD.